. . . "approved"@en . "Flunisolide"@en . . . . "3385-03-3"@en . . "Flunisolidum"@en . . "Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis. The principle mechanism of action of flunisolide is to activate glucocorticoid receptors. It also has anti-inflammatory action."@en . . . . . . . . . . . "Approximately 40% after oral inhalation"@en . . . . . . . . . . . . . . . . . . . . . . . . . . "Absorbed rapidly"@en . . . . . . "investigational"@en . . . "Humans and other mammals"@en . . . "Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin."@en . . . "1.8 hours"@en . . . . . . . . . . . . "Richard E. Jones, Jacquelyn A. Smithers, \"Process for preparing flunisolide.\" U.S. Patent US4273710, issued July, 1965."@en . . . . . . . . "Flunisolide anhydrous"@en . "For the maintenance treatment of asthma as a prophylactic therapy."@en . . . . . . "Flunisolida"@en . . . .